Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Pancragen

Lys-Glu-Asp-Trp, KEDW

Quick Stats
Studies 7
Trials 18
Completed NA INTERVENTIONAL NCT04949607

Traumatic Brain Injury and the Gut Microbiome

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The purpose of the study is to determine whether administration of a prebiotic, inulin, can improve the symptom complex associated with traumatic brain injury and whether inulin administration can alter the bacteria that live in the gut.

Detailed Description

The investigators will study subjects (aged 18-70 years) with a history of moderate/severe traumatic brain injury (n=10) and healthy controls (aged 18-70 years) (n=10). All subjects will undergo a 3-month intervention of oral inulin treatment. The traumatic brain injury subjects will be administered oral inulin twice daily for 3 months. Testing including cognitive function assessment (Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and questionnaires of fatigue, mood and quality of life and sleep will occur at month 0, 3 and 6. Blood sampling for measurement of amino acid levels, hormones, short chain fatty acids and markers of neuroinflammation will be drawn before and 90 minutes (+/- 10 minutes) after a standardized meal will occur at month 0 and month 3. In addition, fecal samples for analysis of the GI microbiome will be collected at month -1, month 0, month 1, month 2, month 3, and month 6 along with an assessment of gastrointestinal health. Traumatic brain injury subjects will be selected from residents at a long term residential rehabilitation center. Healthy control subjects will be administered oral inulin twice daily with meals for 3 months. Quality of life will be assessed by questionnaires at months 0, 3 and 6. Blood sampling for measurement of amino acid levels, hormones, short chain fatty acids and markers of neuroinflammation will be drawn before and 90 minutes (+/- 10 minutes) after a standardized meal will occur at month 0 and month 3. Fecal samples will be collected at month -1, month 0, month 3 and month 6 for analysis of the GI microbiome along with an assessment of gastrointestinal health. A member of the study team will check monthly for adverse events and overall well-being and ensure compliance and ongoing consent.

Interventions

Name: Inulin fructooligosaccharide
Type: DIETARY_SUPPLEMENT
Description: Subjects will be administered inulin at a starting dose of 1g twice daily (2g/day) and ramping up an additional 2g/day until the final dose of 4g twice daily (8g/day), which will continue on until the end of month 3 (week 12). After the month 3 study visit, inulin dosing will begin to ramp down over the next week.

Primary Outcomes

Measure: Characterization of fecal microbiome using molecular methods at baseline
TimeFrame: Baseline
Description: Characterization of the fecal microbiome using a commercially available sampling kit and our lab's patented array for Polymerase Chain Reaction.
Measure: Characterization of fecal microbiome using molecular methods at month 1
TimeFrame: month 1
Description: Characterization of the fecal microbiome using a commercially available sampling kit and our lab's patented array for Polymerase Chain Reaction.
Measure: Characterization of fecal microbiome using molecular methods at month 2
TimeFrame: month 2
Description: Characterization of the fecal microbiome using a commercially available sampling kit and our lab's patented array for Polymerase Chain Reaction.
Measure: Characterization of fecal microbiome using molecular methods at month 3
TimeFrame: month 3
Description: Characterization of the fecal microbiome using a commercially available sampling kit and our lab's patented array for Polymerase Chain Reaction.
Measure: Characterization of fecal microbiome using molecular methods at month 6
TimeFrame: month 6
Description: Characterization of the fecal microbiome using a commercially available sampling kit and our lab's patented array for Polymerase Chain Reaction.

Trial Information

NCT ID

NCT04949607

Status

Completed

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

Centre for Neuro Skills

Last Updated

December 15, 2025

Related Peptides